Cochrane · systematic review · CD010383
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
Greenhalgh, J, Boland, A, Bates, V, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 25%High 6 · 75%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyErlotinib vs control
Population: EGFR M+ patients with NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Erlotinib vs control | HR 0.95 [0.75, 1.22] | 3 studies · 429 participants | High |
Progression‐free survival Erlotinib vs control | HR 0.31 [0.25, 0.39] | 4 studies · 583 participants | High |
Gefitinib vs paclitaxel + carboplatin
Population: EGFR M+ patients with NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Gefitinib vs paclitaxel + carboplatin | HR 0.95 [0.77, 1.18] | 2 studies · 489 participants | High |
Progression‐free survival Gefitinib vs paclitaxel + carboplatin | HR 0.39 [0.32, 0.48] | 2 studies · 485 participants | High |
Gefitinib vs pemetrexed + carboplatin with pemetrexed maintenance
Population: EGFR M+ patients with NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Gefitinib vs pemetrexed + carboplatin with pemetrexed maintenance | HR 0.84 [0.63, 1.11] | 2 studies · 371 participants | Moderate Downgraded: imprecision |
Progression‐free survival Gefitinib vs pemetrexed + carboplatin with pemetrexed maintenance | HR 0.59 [0.46, 0.74] | 2 studies · 371 participants | Moderate Downgraded: risk of bias, imprecision |
Afatinib vs chemotherapy
Population: EGFR M+ patients with NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Afatinib vs chemotherapy | HR 0.91 [0.75, 1.1] | 2 studies · 709 participants | High |
Progression‐free survival Afatinib vs chemotherapy | HR 0.42 [0.34, 0.53] | 2 studies · 709 participants | High |
Erlotinib vs control
Population: EGFR M+ patients with NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Erlotinib vs control | HR 0.95 [0.75, 1.22] | 3 studies · 429 participants | High |
Progression‐free survival Erlotinib vs control | HR 0.3 [0.24, 0.38] | 4 studies · 595 participants | High |
Gefitinib vs paclitaxel + carboplatin
Population: EGFR M+ patients with NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Gefitinib vs paclitaxel + carboplatin | HR 0.95 [0.77, 1.18] | 2 studies · 489 participants | High |
Progression‐free survival Gefitinib vs paclitaxel + carboplatin | HR 0.39 [0.32, 0.48] | 2 studies · 485 participants | High |
Afatinib vs chemotherapy
Population: EGFR M+ patients with NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Afatinib vs chemotherapy | HR 0.93 [0.74, 1.17] | 2 studies · 709 participants | High |
Progression‐free survival Afatinib vs chemotherapy | HR 0.42 [0.34, 0.53] | 2 studies · 709 participants | High |